- $72.85m
- $92.86m
- $192.35m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 2.04 | ||
Price to Tang. Book | 9.04 | ||
Price to Free Cashflow | 6 | ||
Price to Sales | 0.38 | ||
EV to EBITDA | 8.62 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 5.69% | ||
Return on Equity | 7.32% | ||
Operating Margin | 3.11% |
Financial Summary
Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 80.12 | 130.3 | 158.17 | 184.32 | 192.35 | 139.38 | 171.66 | 33.44% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | -6.38 | +85.91 | -1.47 | -38.39 | -65.65 | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Zynex, Inc. is a medical technology company specialized in the manufacturing and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring. The Company’s devices are intended for pain management to reduce reliance on medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current, neuromuscular electrical stimulation and transcutaneous electrical nerve stimulation. The Company’s products include Zynex Medical Products, which includes NexWave, NeuroMove, InWave, E-Wave, M-Wave; Private Labeled Supplies, which includes Electrodes and Batteries; Private Labeled Rehabilitation Products, which include Comfortrac/Saunders, JetStream/Pain Management Technologies, LSO Back Braces, Bracing (Knee and Wrist), and Dynacomp, and Zynex Monitoring Solutions Products, which includes CM-1500, CM-1600, NiCO CO-Oximeter, and HemeOx tHb Oximeter.
Directors
- Thomas Sandgaard CHM (62)
- Daniel Moorhead CFO (48)
- Anna Lucsok COO (35)
- Donald Gregg VPR
- Michael Cress IND (63)
- Joshua Disbrow IND (46)
- Barry Michaels IND (71)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 31st, 2001
- Public Since
- November 27th, 2002
- No. of Shareholders
- 153
- No. of Employees
- 1,000
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market
- Shares in Issue
- 30,227,354

- Address
- 9655 Maroon Circle, ENGLEWOOD, 80112
- Web
- https://www.zynex.com/
- Phone
- +1 8004956670
- Auditors
- Marcum LLP
Upcoming Events for ZYXI
Q1 2025 Zynex Inc Earnings Call
Zynex Inc Annual Shareholders Meeting
Zynex Inc Annual Shareholders Meeting
Q2 2025 Zynex Inc Earnings Release
Q3 2025 Zynex Inc Earnings Release
Similar to ZYXI
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
As of Today at 24:17 UTC, shares in Zynex are trading at $2.41. This share price information is delayed by 15 minutes.
Shares in Zynex last closed at $2.41 and the price had moved by -77.97% over the past 365 days. In terms of relative price strength the Zynex share price has underperformed the S&P500 Index by -79.67% over the past year.
The overall consensus recommendation for Zynex is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreZynex does not currently pay a dividend.
Zynex does not currently pay a dividend.
Zynex does not currently pay a dividend.
To buy shares in Zynex you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.41, shares in Zynex had a market capitalisation of $72.85m.
Here are the trading details for Zynex:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ZYXI
Based on an overall assessment of its quality, value and momentum Zynex is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Zynex is $10.00. That is 314.94% above the last closing price of $2.41.
Analysts covering Zynex currently have a consensus Earnings Per Share (EPS) forecast of -$0.49 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zynex. Over the past six months, its share price has underperformed the S&P500 Index by -72.15%.
As of the last closing price of $2.41, shares in Zynex were trading -66.66% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Zynex PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.41.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Zynex's management team is headed by:
- Thomas Sandgaard - CHM
- Daniel Moorhead - CFO
- Anna Lucsok - COO
- Donald Gregg - VPR
- Michael Cress - IND
- Joshua Disbrow - IND
- Barry Michaels - IND